SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics†or the "Company†), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amended registration statement on Form F-4 (the "Registration Statement†) with the Securities and Exchange Commission (the "SEC†) that includes a management circular/prospectus and other relevant documents related to various proposals contained therein, and that the Registration Statement has been decla. ...